Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study

British Journal of Cancer
Hongnan MoBinghe Xu

Abstract

To assess the safety profile, pharmacokinetics, pharmacodynamics and preliminary antitumour activity of fixed-dose SHR-1210, a novel anti-PD-1 antibody, in advanced solid tumours. A total of 36 patients with advanced solid tumours received intravenous SHR-1210 at 60 mg, 200 mg and 400 mg (4-week interval after first dose followed by a 2-week schedule) until disease progression or intolerable toxicity. The concentration of SHR-1210 was detected for pharmacokinetics, and receptor occupancy on circulating T lymphocytes was assessed for pharmacodynamics. No dose-limiting toxicities were observed. Maximum administered dose was not reached. Most adverse events were grade 1 or 2. Treatment-related severe adverse events were found in two patients. No treatment-related death was reported. Two complete responses (gastric cancer, bladder carcinoma) and seven partial responses were seen. In responders, the median follow-up time was 16.0 months (range 8.3-19.5), and the median duration of response was not reached (range 2.7-17.5+ months). The half-life of SHR-1210 was 2.94 d, 5.61 d and 11.0 d for 3 dose levels, respectively. Our results demonstrated a promising antitumour activity and a manageable safety profile of SHR-1210, displayed an e...Continue Reading

References

Nov 28, 2002·The British Journal of Dermatology·V Piguet, L Borradori
Jul 22, 2009·Journal of Clinical Pharmacology·Diane D WangKourosh Parivar
Nov 26, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jedd D WolchokF Stephen Hodi
Jun 16, 2010·The British Journal of Dermatology·B M PiracciniB Richert
Jan 15, 2011·Journal of Clinical Pharmacology·Shuzhong ZhangDiane D Wang
Jan 20, 2012·Clinical Pharmacokinetics·Shuang BaiMark J Dresser
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Apr 10, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Janis M TaubeRobert A Anders
Apr 22, 2015·The New England Journal of Medicine·Edward B GaronUNKNOWN KEYNOTE-001 Investigators
May 6, 2015·The Lancet Oncology·Josefine Gibson
May 4, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rita NandaLaurence Buisseret
Sep 21, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Laura Q M ChowTanguy Y Seiwert
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Dec 27, 2016·Frontiers in Immunology·Kankana BardhanVassiliki A Boussiotis
Feb 18, 2017·The New England Journal of Medicine·Joaquim BellmuntUNKNOWN KEYNOTE-045 Investigators
Mar 23, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joshua BaumlRobert Haddad
May 19, 2017·Journal for Immunotherapy of Cancer·Tomoko FreshwaterJulie A Stone
Nov 3, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean-Sebastien FrenelAndrea Varga
Jan 24, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jing HuangYuchen Jiao

❮ Previous
Next ❯

Citations

Dec 6, 2018·MAbs·Hélène Kaplon, Janice M Reichert
Jul 18, 2019·Drugs·Anthony Markham, Susan J Keam
Jan 25, 2020·Expert Opinion on Drug Metabolism & Toxicology·Danilo RoccoCesare Gridelli
Mar 2, 2019·The Oncologist·Wenfeng FangLi Zhang
Aug 9, 2020·Expert Review of Gastroenterology & Hepatology·Zhongguang ChenKelly Koral
Feb 29, 2020·World Journal of Clinical Cases·Qing Yu, Wen-Xia Wang
Jun 27, 2019·World Journal of Clinical Cases·Cong YanHang-Yu Zhang
Apr 8, 2020·Drug Design, Development and Therapy·Jason D LickliterTarek Meniawy
Jun 6, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Qian MeiWeidong Han
Aug 20, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yuqin SongJun Zhu
Nov 4, 2020·Drug Metabolism Reviews·Seyyed Mojtaba MousaviSargol Mazraedoost
Mar 27, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Zhi PengLin Shen
Aug 6, 2021·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Jian HeLiting Qian
Aug 18, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yuan-Yuan QuDing-Wei Ye

❮ Previous
Next ❯

Methods Mentioned

BETA
enzyme-linked immunosorbent assay
ELISA
Assay
bone marrow aspiration
biopsy

Clinical Trials Mentioned

NCT02742935

Software Mentioned

WinNonlin
SPSS

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Jing HuangYuchen Jiao
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
A PatnaikAnthony W Tolcher
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Wim W Ten Bokkel HuininkA M Oza
European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Eric Van CutsemOlivier Rixe
© 2022 Meta ULC. All rights reserved